Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism

• Published in: Diabetes, metabolic syndrome and obesity Vol. 13; pp. 4353 - 4359
• Main Authors: Kawarasaki, Satoko, Sawazaki, Honami, Iijima, Hiroaki, Ng, Su-Ping, Kwon, Jungin, Mohri, Shinsuke, Iwase, Mari, Jheng, Huei-Fen, Takahashi, Haruya, Nomura, Wataru, Inoue, Kazuo, Kawada, Teruo, Goto, Tsuyoshi
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2020; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Analysis; Animal experimentation; Animals; Antidiabetics; Body composition; Body weight; Dextrose; Diabetes; Diet; dosing method; Fatty acids; Food; Glucose; Liver; Metabolism; Obesity; Physiological aspects; sglt2 inhibitor; Short Report; Statistical analysis; Synthesis; Type 2 diabetes; Japan; dosing method; SGLT2 inhibitor; obesity
• ISSN: 1178-7007; 1178-7007
• DOI: 10.2147/dmso.s269916

Sodium-glucose co-transporter-2 (SGLT2) inhibitors have various pleiotropic effects, including body weight reduction, and therefore have the potential to be used in various applications. However, such effects have not been fully investigated; thus, non-clinical studies using animal models are needed. In animal experiments, SGLT2 inhibitors are usually administered by oral or dietary methods. However, the detailed characteristics of these dosing methods, especially to induce their pleiotropic effects, have not been reported. Therefore, we compared the preventive effects of canagliflozin, an SGLT2 inhibitor, on body weight gain following oral gavage and dietary administration methods in a mouse model of diet-induced obesity. Canagliflozin was dosed by oral gavage or dietary administration for 9 weeks to 6-week-old C57BL/6N mice fed a high-fat diet, and parameters related to obesity were evaluated. The suppression of body weight gain, fat mass, and hepatic lipid content was observed following both dosing methods, whereas the effect on body weight tended to be stronger in the dietary administration group. In adipose tissue, fatty acid synthase expression was significantly decreased in the dietary administration group, and its expression was significantly correlated with fat mass. However, the expression of genes related to fatty acid oxidation was unchanged, indicating that the preventive effect on body weight gain was mediated mainly through the suppression of lipid synthesis rather than the promotion of lipid oxidation. Canagliflozin prevented body weight gain through the suppression of lipid synthesis via both dosing methods, although there were some differences in the efficacy. The findings of our study can help to identify new mechanisms of action of SGLT2 inhibitors and potential applications.